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Multiple sclerosis (MS) is the autoimmune disease of the central nervous system with complex pathogenesis, different clinical
courses and recurrent neurological relapses and/or progression. Despite various scientific papers that focused on early stage of MS,
our study targets selective group of late stage secondary progressiveMSpatients.Thepresentedwork is concernedwith the reactivity
of blood platelets in primary hemostasis in SPMS patients. 50 SPMS patients and 50 healthy volunteers (never diagnosed with MS
or other chronic diseases) were examined to evaluate the biological activity of blood platelets (adhesion, aggregation), especially
their response to the most important physiological agonists (thrombin, ADP, and collagen) and the effect of oxidative stress on
platelet activity. We found that the blood platelets from SP MS patients were significantly more sensitive to all used agonists in
comparison with control group. Moreover, the platelet hemostatic function was advanced in patients suffering from SP MS and
positively correlated with increased production of O
2
−∙ in these cells, as well as with Expanded Disability Status Scale. We postulate
that the increased oxidative stress in blood platelets in SP MS may be primarily responsible for the altered haemostatic properties
of blood platelets.
1. Introduction
Multiple sclerosis (MS) is a chronic autoimmune, inflam-
matory, and demyelinating disease involving demyelination
of nerve sheath and disintegration of axons of the central
nervous system (CNS), leading to disturbances of neuro-
transmission processes and, consequently, to occurrence of
the neurological symptoms. On the clinical and pathological
grounds, MS is a heterogeneous disease, and therefore differ-
ent biological pathwaysmay be active in differentMS patients
[1].
Clinically there are four main subtypes of MS: relapsing-
remitting (RR MS), primary progressive (PP MS), secondary
progressive (SP MS), and also progressive relapsing (PR MS)
[2].
The most prevalent form of MS is RR MS, where disease
fluctuates between periods of inflammation/demyelination
and remission. Finally, after several years of the disease
duration, RR MS in approximately 70% of cases turns into
a secondary progressive disease in which patients suffer
irreversible disability progression [3]. The progressive phase
of multiple sclerosis depends on neuronal degeneration
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and cortical atrophy [4]. Accumulated data indicates that
oxidative stress (OS) plays a critical role in this process [5, 6].
Other mechanisms responsible for the disease develop-
ment in patients with SP MS have not been definitely rec-
ognized yet, although OS resulting in mitochondrial injury
might also participate in the induction of demyelination
and neurodegeneration in progressive stages of MS. OS, in
both the relapsing-remitting and the progressive stages of
MS, seems to be primarily powered by inflammation and
oxidative burst in microglia; however, its effects might get
amplified in patients with SP MS by age-dependent iron
accumulation in the brain as well as by mitochondrial gene
deletions, elicited by the chronic inflammatory process [7].
The MS duration is one of the main risk factors of
stroke and deep vein thrombosis [8]. It has been shown that
the coagulation cascade, leading to the generation of large
amounts of thrombin responsible also for platelet activation,
may play a key role in the development of inflammation in
MS [9]. The recent data also indicates that blood platelets
could be a potential therapy target in MS, since they are
implicated in the development of neuroinflammatory process
associated with this disorder. Various compounds stored
in platelet 𝛼-granules can affect the permeability of BBB
and are crucial for the infiltration of T-lymphocytes which
are responsible for the dissemination of new inflamma-
tory lesions in the nervous system in RR MS [10]. Many
physiological agonists activate platelets and, consequently,
cause their adhesion, secretion of compounds stored in their
granules, microparticle formation, and receptor expression
which finally induces platelet aggregation. The excessively
activated blood platelets by endogenous agonists contribute
to the disturbances in various diseases [11]. The coagulation
cascade itself plays a major role in the development of an
inflammatory response in MS [8]. Thrombin is the major
coagulation factor of blood clotting cascade responsible for
conversion of fibrinogen to fibrin [12], as well as the most
potent activator of platelets, responsible for prothrombotic
platelet function [12]. Proteomic studies of laser-captured
microdissected lesions reported in the transcriptional profil-
ing inMS [13] illuminated a key role for the thrombin cascade
in the development of inflammation in MS. However, the
triggering mechanism for platelet activation process and the
role of platelets in hemostasis in a further development of the
disease in the secondary progressive stage are still not clear.
Our previous studies show thatOSmight be a very impor-
tant phenomenon in MS [14, 15]. As it has been known, OS is
involved inmany chronic diseases, such as neurodegenerative
and cardiovascular disorders.The overproduction of reactive
oxygen specials (ROS), observed as a major driving factor
of demyelination and neurodegeneration in progressive MS
[3], has important pathophysiological implications and may
modulate physiological response of blood platelets (which are
involved in hemostasis). ROS are implicated in regulation of
platelet function andmay be produced as secondmessengers,
in the receptor-mediated signaling pathways during platelet
activation.
In the presented work, we focused on one course of MS
to make our work more precise in this heterogenic disorder.
Therefore, our study assessed the adhesion of thrombin-stim-
ulated and nonstimulated human blood platelets to collagen
or fibrinogen. In our studies, we determined the reactivity of
blood platelets evaluated by their ability to aggregate, upon
stimulation with different strong agonists: ADP and collagen.
Another goal of our study was to show the link between
ROS generation and platelet hyperactivation in secondary
progressive stage of MS. In addition to the tests for the
biological activity of blood platelets, we examined the level of
OS in platelets by measuring the concentration of superoxide
anion radicals generated in these cells.We correlated the level
of O
2
−∙ formed in blood platelets with hemostatic activity
of platelets expressed as their adhesion and aggregation. In
blood platelets mainly O
2
−∙ is generated. It can scavenge
endothelial-derived NO in a fast reaction generating per-
oxynitrite (ONOO−), a significant pathogenic factor that is
responsible for neuron damage to neuron in MS.
2. Materials and Methods
2.1. Demographic and Clinical Characteristics. The blood
samples were collected from 50 patients (male 𝑛 = 22; female
𝑛 = 28), suffering from secondary progressive (SP) course
of MS. The patients were observed for one year before the
blood collection. When initial relapsing-remitting course is
followed by progression, with or without occasional relapses,
minor remissions, and plateaux, the SPMS can be recognized.
McDonald’s criteria were used to diagnose the MS. The
clinical parameters in patients withMS aremean age of 48.2±
15.2 years, disability status scale (EDSS) of 5.5±1.8 andmean
disease duration of 14.3±8.3 years, andmodifiedRankin scale
of 2–4. The blood samples were delivered from Neurological
Rehabilitation Division III General Hospital in Lodz, Poland.
The control blood samples were obtained from fifty
healthy volunteers (male 𝑛 = 19; female 𝑛 = 31), not taking
any medications, who have never been diagnosed with MS
or other chronic diseases and without any neurological or
hormonal illness and any chronic inflammatory disease. The
control groups and patients with MS (Table 1) were matched
by the age and sex.
These two populations (control andMS) were statistically
compared, which confirmed the homology between these
groups in age, BMI, and gender.
The protocol and all procedures were done accord-
ing to Helsinki Declaration and were approved by Ethics
Committee of the Medical University of Lodz, Poland,
RNN/260/08/KB.
2.2. Isolation of Human Blood Platelets. The blood samples
were collected into CPDA-1 (citrate phosphate dextrose
adenine-1), taken from a peripheral vein between 8 and
9 am. The blood platelets were isolated by differential
centrifugation of blood as described by Wachowicz and
Kustron´ (1992) [16] and counted by the photometric method
according to Walkowiak et al. (1989) [17]. The platelets were
washed and resuspended in modified Tyrode’s (Ca2+/Mg2+)
free buffer (127mM NaCl, 2.7mM KCl, 0.5mM NaH
2
PO
4
,
12mMNaHCO
3
, 5mMHEPES, 5.6mMglucose, and pH7.4).
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Table 1: The characteristics of study subjects and control groups.
Healthy controls SPMS
(𝑛 = 50) (𝑛 = 50)
Mean age [years] 45.7 ± 10.2 48.2 ± 15.2
Gender [𝑛 (frequency])
Male 19 22
Female 31 28
EDSS — 5.5 ± 1.8
Mean disease duration [years] — 14.3 ± 8.3
EDSS: Expanded Disability Status Scale; SPMS: secondary progressive
multiple sclerosis.
2.3. Reagents. ADP was obtained from Chrono-Log Corpo-
ration (Havertown, PA), divided into small 500𝜇mol/L stock
aliquots and stored at 2–8∘C until use (for adhesion and
aggregation). Collagen type I, bovine serum albumin (BSA),
and bicinchoninic acid (BCA) solution were delivered from
Sigma (St. Louis, MO, USA). Thrombin was purchased from
BioMed (Lublin). Fibrinogen was prepared from citrated
human plasma, by the combination of cold and ethanol
precipitations technique by Doolittles’ method [18].
2.4. Platelet Adhesion. The adhesion of blood platelets to
fibrinogen or collagen type I was determined according to
Tuszyn´ski and Murphy methods [12]. The platelet adhesion
measurement was based on ELISAmethod.The first step was
to coat each well of Nunc microplatelet (MaxiSorp) by the
protein coat, fibrinogen or collagen. The application volume
of the fibrinogen or collagen was 100 𝜇L per well for a 96-
well plate at the final concentration of 0.1 U/mL. The coat
microplatelet was incubated for 16 h at 4∘C. After incubation,
to remove the unbound proteins, the microplatelet was
washed three times with 200 𝜇L of PBS. Then, 200𝜇L of
1% bovine albumin was added onto the coated wells. The
microplatelet was incubated for 2 h at 37∘C. The excess of
bovine albumin was poured off and the microplate was
washed three times with 200 𝜇L of PBS. To each well, 100 𝜇L
of platelet suspension (3 × 108 platelets/mL) was added. In
order to activate the blood platelets, 50𝜇L of thrombin at
the final concentration of 0,6U/mL was added to the platelet
suspension. The microplatelet was incubated for 2 h at 37∘C.
The nonadherent cells were removed by washing with 200 𝜇L
of PBS. To determine the total protein concentration, each
well was incubated for 1 h at 37∘C with 200𝜇L of Sigma BCA
working solutions and after incubation the microplatelet was
spectrophotometrically measured at 562 nm with a platelet
reader.
2.5. Platelet Aggregation. The whole blood was centrifuged
for 10min at 250×g at room temperature to get platelet-
rich-plasma (PRP). The platelet aggregation was measured
in platelet-rich-plasma (PRP) by turbidimetric method using
the optical Chrono-Log aggregometer (Chrono-Log, Haver-
town, PA). After preincubation of PRP (3 × 108 platelets/mL)
at 37∘C for 5min, the agonist solutions were added: ADP
(10 𝜇M) or collagen (2𝜇g/mL). The aggregation was mea-
sured with stirring by the duration of 10 minutes. The results
are presented as a percentage of the aggregation.Themaximal
aggregation (100%) was defined as the maximum change in
light transmission, observed in PPP (platelet-poor-plasma).
2.6. O
2
−∙ Generation. The generation of superoxide anion
radicals (O
2
−∙) in SP MS and in the control platelets was
measured by the cytochrome c reduction, as described
earlier [19]. For that purpose, one mL of cytochrome c
(160 𝜇M) prepared in Ca2+/Mg2+ free Tyrode’s buffer was
added to an equal volume of platelet suspensions in the
same buffer. After incubation, the platelets were sedimented
by centrifugation at 2000×g for 5min and the supernatants
were added to cuvettes. The reduction of cytochrome c was
measured spectrophotometrically at 550 nm. To calculate the
molar concentration of O
2
−∙, an extinction coefficient for
cytochrome c of 18700M−1 cm−1 was used [20].
2.7. Statistical Analysis. The results were statistically elab-
orated. The values were expressed as means ± SD. The
Shapiro-Wilk test was used for checking the normality of the
distribution of examined data. Student’s 𝑡-test was used for
the normal distribution or Mann-Whitney 𝑈 test when the
distribution was nonnormal.
The analysis of correlation parameters for the superoxide
anion generation in blood platelets, the platelets adhesion to
fibrinogen/collagen, and the aggregation were estimated by
Spearman’s rank correlation. For all correlations, Spearman’s
rank correlation coefficient was estimated and plot regression
was performed. Similarly, we analyzed the dependence of
platelet aggregation and the ExpandedDisability Status Scale,
as well as the relationship between EDSS and Beck Depres-
sion Inventory.
The statistical analysis was performed using StatsDirect
Statistical software version 2.7.2. 𝑝 < 0.05 was considered as
statistically significant.
3. Results
Our results indicate that platelets from SP MS patients show
statistically significant increase of adhesion (Figures 1 and 2)
and aggregation (Figures 3 and 4).
The adhesion of blood platelets obtained from both
healthy controls and SP MS patients is shown in Figures 1
and 2. Our results demonstrate that the adhesion of blood
platelets to fibrinogen (Figures 1(a) and 2(a)) and to collagen
type I (Figures 1(b) and 2(b)) wasmarkedly higher in platelets
from patients with SP MS than in healthy subjects. The
platelets obtained from SP MS, both unstimulated (resting)
(Figures 1(a) and 1(b)) and stimulated with 0.6U/mL throm-
bin (Figures 2(a) and 2(b)), showed the distinctly enhanced
adhesion (𝑝 < 0.0001). The adhesion level of SP MS
was about 20–35% higher in comparison with the control
platelets. The adhesion of control platelets from healthy
subjects was expressed as 100%. We also observed the statis-
tically significant enhancement of the aggregation of platelets
obtained from SP MS group compared to healthy control
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Figure 1: The adhesion of resting platelets to fibrinogen (2mg/mL) (a) or collagen (0.1 U/mL) (b). The data are presented as means ± SD
(𝑛 = 50; ∗𝑝 < 0.0001 SP MS platelets versus control (without MS) by Mann-Whitney 𝑈 test).
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Figure 2: The adhesion of thrombin-activated platelets to fibrinogen (2mg/mL) (a) or collagen (0.1 U/mL) (b). The data are presented as
means ± SD (𝑛 = 50; ∗𝑝 < 0.0001 SP MS versus control (without MS) by Mann-Whitney 𝑈 test).
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Figure 3: The blood platelet aggregation induced by ADP in platelet-rich-plasma (PRP). (a) The data are presented as means ± SD (𝑛 = 50;
∗
𝑝 < 0.0001 SP MS platelets versus control (without MS) by Mann-Whitney 𝑈 test). (b) The typical curve of platelet aggregation after
stimulation of platelets by ADP (Chrono-Log aggregometer, Havertown, PA).
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Figure 4:The blood platelet aggregation induced by collagen in platelet-rich-plasma (PRP). (a)The data are presented asmeans ± SD (𝑛 = 50;
∗
𝑝 < 0.0001 SP MS platelets versus control (without MS) by Mann-Whitney 𝑈 test). (b) The typical curve of platelet aggregation after
stimulation of platelets by ADP (Chrono-Log aggregometer, Havertown, PA).
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Figure 5: The generation of superoxide anion radicals in blood platelets from SP MS patients. The results are done in triplicate and are
expressed as means ± SD (𝑛 = 50, ∗𝑝 < 0.001 versus control (without MS) by Student’s 𝑡-test).
(Figures 3 and 4). The level of platelet aggregation upon
ADP stimulation increased from 83% for healthy controls to
98% for SP MS patients (growth of 18% of control, when the
value of the control was taken as 100%) (Figure 3(a)). The
aggregation induced by collagenwas enhanced from87.5% for
healthy persons to 99% for SP MS patients (the 13% growth
of control) (Figure 4(a)).
The other set of experiments involved the measurement
of the level of O
2
−∙ generation in blood platelets. The con-
centration level of O
2
−∙ was statistically significantly elevated
in blood platelets obtained from SP MS patients compared
to healthy volunteers (𝑝 < 0.001). The level of O
2
−∙ reached
a mean value of 0.305 nmol/mg of platelet proteins (SD =
0.03) in platelets of SP MS patients while for healthy controls
the level reached a mean value of 0.469 nmol/mg of platelet
proteins (SD = 0.04), respectively (Figure 5).
Importantly, we found statistically significant positive
correlation between the increase of thrombin-stimulated
blood platelets adhesion and degree of O
2
−∙ generation in
blood platelets in SP MS patients (Figures 6(a) and 6(b)
and Table 2), as well as between collagen-induced platelet
aggregation and O
2
−∙ generation in blood platelets in SP
MS patients (Figure 6(c) and Table 2). In all cases, we
observed statistically significant (𝑝 < 0.0001) positive cor-
relation between the superoxide anion generation and the
platelet adhesion or aggregation. Spearman’s rank correlation
coefficients were, respectively, 0.88001 for platelet adhesion
to fibrinogen, 0.860597 for platelet adhesion to collagen, and
0.881833 for the platelet aggregation (Table 2).
We also demonstrated the relationship between Expand-
ed Disability Status Scale (EDSS) and blood platelet aggrega-
tion level. Statistically significant (𝑝 < 0.0001) positive cor-
relation was observed between EDSS and platelet aggregation
induced by both ADP and collagen (Spearman’s rank correla-
tion coefficients were, resp., 0.568162 and 0.610421) (Figures
7(a) and 7(b) and Table 3).
Additionally, we checked the dependence of EDSS and
other clinical parameters.The analysis showed the statistically
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Table 2: The correlation parameters values obtained for blood platelet hemostatic functions and degree of O
2
−∙ generation in samples from
SP MS patients. The rank correlation coefficients and probability of correlation are presented.
Blood platelet haemostatic functions
The adhesion of thrombin-stimulated
platelets to fibrinogen
The adhesion of thrombin-stimulated
platelets to collagen Platelet aggregation induced by ADP
Rho 𝑝 Rho 𝑝 Rho 𝑝
O
2
−∙ 0.88001 𝑝 < 0.0001 0.860597 𝑝 < 0.0001 0.8818 𝑝 < 0.0001
Rho: rank correlation coefficient.
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Figure 6:The correlation analysis between the superoxide anion level in blood platelets and the platelet adhesion to fibrinogen (a) or collagen
(b) or the platelet aggregation induced by collagen (c) (Spearman’s rank correlation).
significant (𝑝 < 0.0001) positive correlation (Rho=0,674675)
between EDSS and Beck Depression Inventory (Figure 7(c)).
In this study, we did not find statistically significant
correlation between plasma concentrations of investigated
compounds and age, BMI, and mean disease duration in SP
MS patients.
4. Discussion
The coagulation cascade plays the critical role in the develop-
ment of an inflammatory response in MS. Langer et al. [21]
proved that platelets are trapped in chronic active demyeli-
nating MS lesion. They also observed that, after inhibiting
the main platelets receptors, GP IIb/IIIa, the paralysis and
experimental autoimmune encephalomyelitis were, respec-
tively, ameliorated and reduced. Such findings are a great
opportunity to consider that the glycoprotein IIb/IIIa block-
ers, like Abciximab, may play a crucial role in MS and other
demyelinating diseases.
The proteomic studies pointed out a great role of throm-
bin cascade in the development of inflammation in MS
[9, 22].
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Figure 7:The correlation analysis between the Expanded Disability Status Scale and the platelet aggregation induced by ADP (a) or collagen
(b) or the Beck Depression Inventory (c) (Spearman’s rank correlation).
Table 3: The correlation parameters values obtained for Expanded Disability Status Scale and blood platelet aggregation level. The rank
correlation coefficients and probability of correlation are presented.
Blood platelet haemostatic functions
Platelet aggregation induced by ADP Platelet aggregation induced by collagen
Rho 𝑝 Rho 𝑝
EDDS 0.568162 𝑝 < 0.0001 0.610421 𝑝 < 0.0001
EDSS: Expanded Disability Status Scale; Rho: rank correlation coefficient.
The blood platelets are the main elements of the cellular
hemostasis and also play an important role in the coagulation
cascade.These multifunctional cells are activated by different
endogenous, physiological agonists, including ADP, collagen,
or thrombin, due to the vast number of receptors present on
the surface of platelets. Upon vessel wall injury circulating
platelets are immediately immobilized by interactions with
vWF bounding to collagen and the glycoprotein GPIb-V-IX
complex [23] which initiates adhesion of flowing platelets to
the subendothelial extracellular matrix (ECM).
In the present study, we focused on the primary hemosta-
sis in patients with SP MS. Our studies were designed to
demonstrate the changes in platelet hemostatic function
of patients suffering from secondary progressive multiple
sclerosis in comparison with healthy control group.
In the 1950s, there were a few early studies on the role of
blood platelets in the central nervous system demyelination,
which showed the increased adhesion of platelets in the MS
[23]. Since that time, next papers were published confirming
the platelet abnormalities in MS patients [24]. The studies of
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Sheremata et al. [25] demonstrated that blood platelets are
significantly activated in MS patients [25]. To investigate the
basis of these observations, the authors have applied the flow
cytometric analysis tomeasure the platelet-derivedmicropar-
ticles (PMP) and platelet microaggregates formation, as well
as an expression of platelet activation marker CD62P (P-
selectin) [25]. Their findings indicate the elevated platelet
activation in clinically stable relapsing-remitting MS patients
and confirm the conclusion presented in the earlier literature
that platelets are chronically activated in RR MS.
The significant role of activated platelets in the develop-
ment of inflammatory response is directly related to their
adhesion to inflamed changed endothelial cells or proteins
presented in the subendothelial layer of blood vessel wall
and to tendency of blood platelets to form aggregates with
leukocytes [26, 27]. The platelets are able to directly activate
both leukocytes and dendritic cells. There have been reports
that suggested the hypothesis that the interaction of platelets
with leukocytes and endothelial cells is directly responsible
for the disruption of the BBB and considered as the key initial
step of the disease process in someneurological inflammatory
diseases, includingMS, leading to infiltration of lymphocytes
and further to the formation of inflammatory lesions in the
brain [28].
All of cited reports emphasize the importance of platelet
activation in MS. However, as highlighted by the authors of
these studies [25], the role of platelets in pathogenesis of
MS remains unknown, and the further studies are required
to validate the significance of the existing study and to
determine the role of platelet activation in neuropathogenesis
of MS. In addition, there are very few data describing the
physiology of platelets in the secondary progressive phase of
MS. Among the existing reports, the differences in platelet
activation parameters between RR MS and SP MS exist.
Higher level of sP-selectin and other markers of platelet
activation [29] as well as an increase of PAF activity [30]
were observed in RR MS compared to secondary progressive
MS. Due to the fact that each clinical phase of MS should be
considered as a distinct disease entity [31], we focused our
attention on the alterations of platelets in SPMS characterized
by irreversible disability progression [3].
Our results demonstrate that the activation of platelets
from SP MS patients is significantly elevated compared to
the activation of platelets from healthy subjects. The level of
platelet aggregation induced by physiological agonists (ADP,
collagen) and adhesion to the two key adhesion proteins
(collagen and fibrinogen) in patients with SP MS is greater
than in the control group. We clearly indicate that SP MS
platelets are more sensitive to agonists and their response is
significantly stronger than platelets obtained from the healthy
subjects. Our observation of chronically increased platelet
activation is consistent with other studies.
The oxidative stress has been implicated in the patho-
physiology of MS, but its relation to disease progression as
well as to the functioning of hemostasis is uncertain. The
studies of Bo¨ et al. [32] implicate the free radical nitric
oxide role in the pathogenesis of demyelinating MS lesions
because of the markedly elevated human inducible nitric
oxide synthase in tissue sections from MS [32]. In the fast
reaction between ∙NO and O
2
−∙, short-lived species capable
of inducing oxidative/nitrative changes in a wide variety
of biomolecules are produced. Among them, the highest
reactivity exhibits peroxynitrite (PN, ONOO−) [33]. PN
is an important pathogenetic factor in MS, which causes
the increased activity of inflammatory processes. ONOO−
generated in the circulatory system is a major redox imbal-
ances factor involved in the disturbance of hemostasis. It
is responsible for damage of plasma components and cells
[1]. Many pathogenic processes, including blood platelet
hyperactivity, may be initiated by injury action of free radical
species [34]. During platelet activation mainly O
2
−∙ and
other ROS are produced [35]; therefore, blood platelets link
the processes of hemostasis, thrombosis, and inflammation
[36].
It is possible that the platelet intercellular mechanisms of
activation where ROS take place may be modulated during
progression of disease status in MS. However, we are not
sure if the activation of blood platelets in SP MS is simply
a consequence of general inflammation and overproduction
of reactive oxygen and nitrogen species. The epidemiological
data highlight the high risk of cardiovascular disease in the
course of MS [37]. Thus, it is possible that the increased
platelet activation may be a component of procoagulant state
in this disease. We observed a positive correlation between
the level of O
2
−∙ (measured by the method of cytochrome c
reduction) in blood platelets and two steps of their activation,
for example, amplified adhesion and elevated aggregation
(Figure 6 and Table 2).
The superoxide radicals may interact with iron (accu-
mulated in the brain in SP MS) and form reactive hydroxyl
radicals that attack polyunsaturated fatty acids, leading
to lipid peroxidation and demyelination. Moreover, based
on the hypothesis that mitochondrial injury, induced by
ROS/RNS, is a major driving factor of demyelination and
neurodegeneration in progressiveMS [3], wemight postulate
that excessive platelet reactivity in SP MS is the result of
increasedOS in blood platelets. In progressiveMS, in chronic
active and inactive lesions, the number of mitochondria is
increased and the enzymatic activity of the respiratory chain
is altered [38, 39].
5. Conclusion
We measured the platelet aggregation and adhesion as the
markers of hemostatic activity of blood platelets.Our findings
demonstrate the changes of platelet hemostatic function in
patients suffering from SP MS in comparison with healthy
subjects, who have never been diagnosed with MS or other
chronic diseases. In our study, we have shown that platelet
activity in patients with SP MS is significantly higher than
in healthy controls. Our results demonstrate that platelet
reactivity and aggregation induced by ADP or collagen in
blood platelets from SP MS patients are greater than aggre-
gation of platelets obtained from healthy volunteers. Fur-
thermore, blood platelet aggregation is positively correlated
with the degree of disability of patients. The level of platelet
aggregation induced by major physiological agonists (ADP,
collagen) has reached, respectively, 90% and 98% in patients
Oxidative Medicine and Cellular Longevity 9
with SPMS.We also observed a significant increase in platelet
adhesion to collagen or fibrinogen (30% in comparison with
control group). These findings suggest that platelets from
SP MS patients are significantly more sensitive to the key
physiological agonists, which may be an important cause of
hemostatic disorders occurring in SP MS.
Moreover, our results show the positive correlation
between the level of O
2
−∙ generation and changes of platelet
hemostatic responses in SP MS patients.
Considering the data presented in this study, we suggest
that blood platelets actively participate in oxidative stress
existing in SP MS. The production of O
2
−∙ in these cells, one
of the main substrates for the formation of peroxynitrite, can
adjust the changes in platelet hemostasis in progressive stage
of MS. Further investigations are continuing.
Understanding platelet pathophysiology provides real
new therapeutic targets in MS. It seems that blood platelets
are important determinants in the MS pathogenesis, but
the use of antiplatelet agents (inhibiting platelet activation)
requires the inclusion of antioxidants, especially in progres-
sive stages of disease.
The role of platelet in MS especially during different
subtypes of MS required further studies.
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